Atlas FDA

CONTIGEN (TM) BARD (R) COLLAGEN IMPLANT

FDA premarket approval P900030 · decided 1993-09-30

Approval details

PMA number
P900030
Trade name
CONTIGEN (TM) BARD (R) COLLAGEN IMPLANT
Generic name
AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE
Applicant
Allergan, Inc.
Date received
1990-04-27
Decision date
1993-09-30
Days to decision
1252 days
Decision code
APWD
Product code
LNM
Advisory committee
Gastroenterology, Urology
Expedited review
No
Location
Goleta, CA
Statement
Approval for the Contigen™ Bard® Collagen Implant. This device is indicated for use in the treatment of urinary incontinence due to intrinsic sphincter deficiency (poor or non-functioning bladder outlet mechanism) that may be helped by a locally injected bulking agent. Contigen implant therapy is intended only for patients who have shown no improvement in their incontinence for at least 12 months.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
REFRESH RELIEVA For CONTACTS (K190674)Allergan, Inc.2019-08-08
XEN Glaucoma Treatment System (K161457)Allergan, Inc.2016-11-21
Natrelle 133 Plus Tissue Expander (K143354)Allergan, Inc.2015-08-20
REFRESH OPTIVE LENS COMFORT REWETTING DROPS (K083812)Allergan, Inc.2009-07-09
SINGLE AMPLIFIER FOR BOTOX (K051852)Allergan, Inc.2005-09-14
COMPLETE BRAND MULTI-PURPOSE SOLUTION (K014202)Allergan, Inc.2002-02-20
COMPLETE BRAND MULTI-PURPOSE SOLUTION (K013479)Allergan, Inc.2002-02-11
COMPLETE BRAND MULTI-PURPOSE SOLUTION (K003252)Allergan, Inc.2001-02-21